Table 1.
Clinical activity of novel therapeutics in peripheral T-cell lymphoma
| ORR | CR rate | ORR PTCL-NOS | ORR AITL | ORR ALCL | |
|---|---|---|---|---|---|
| FDA approved | |||||
| Histone deacetylase inhibitors | |||||
| Romidepsin | 25% | 15% | 29% | 30% | 24% |
| Belinostat15 | 26% | 11% | 23% | 54% | 15% |
| Antifolate | |||||
| Pralatrexate14 | 29% | 15% | 32% | 8% | 29% |
| CD30-targeted approaches | |||||
| Brentuximab vedotin26,44 | 69% | 44% | 33% | 54% | 86% |
| Novel agents | |||||
| Alk inhibition | |||||
| Crizotinib32 | 88%† | ||||
| PI3 kinase inhibitors | |||||
| Duvelisib28,29* | 50% | 22% | |||
| JAK inhibition | |||||
| Ruxolitinib36 | 27% | 8% | |||
| Cerdulatinib39 | 35% | 31% | |||
| Hypomethylating agents | |||||
| 5-Azacitadine45 | 53% | 32% |
This table summarizes the clinical activity of FDA-approved agents as well as agents under investigation for the treatment of relapsed/refractory peripheral T-cell lymphoma.
*
The data presented regarding duvelisib represents a pooled analysis of patients treated with single-agent duvelisib in 2 different studies.
†
Crizotinib has been studied only in relapsed anaplastic large cell lymphoma.